18 December 2009 10:47 PM+ 7 ( 93 days ago)
Discuss
|
|
Bury
| Tagged:
us
BOSTON (Reuters) - Celgene Corp said on Friday that initial results from a clinical trial showed multiple myeloma patients who took its drug Revlimid following a stem cell transplant had a 58 percent reduction in risk of their disease progressing.... us
To comment or read full article login. No account? Register free.
online 43